Figure 1From: Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study Distribution of the number of infusions of Mitoxantrone*. *Includes only patients who received at least one dose of Mitoxantrone.Back to article page